Aethlon Medical (AEMD) Corporate presentation summary

Investment highlights

• Patented Hemopurifier platform demonstrates clearance of enveloped viruses and extracellular vesicles in vitro and in patients, with two FDA Breakthrough Device designations.

• Multi-indication potential spans oncology, infectious diseases, and transplant, supported by a strong IP portfolio and capital-efficient development.

• Early clinical data show favorable safety profile across 173 treatments in 44 patients.

• Supported by Australia’s R&D Tax Incentive program, offering up to 43.5% cash benefit for eligible R&D expenditures.

Hemopurifier mechanism and clinical progress

• Proprietary technology uses a dialysis-like cartridge with GNA lectin affinity resin to capture extracellular vesicles and enveloped viruses from blood.

• Demonstrated removal of tumor-derived EVs and life-threatening viruses, with ongoing oncology trials in Australia showing no dose-limiting toxicities.

• In vitro and in vivo studies confirm removal of cancer-derived EVs and reduction of exosome concentrations in cancer and COVID-19 patients.

• Current oncology trial progressing through cohorts, with upcoming data on EV removal and anti-tumor CD8 T cell changes.

Market opportunity and disease applications

• Addresses large and growing checkpoint inhibitor market, targeting 60-70% of patients who do not respond to current PD-1/PD-L1 therapies.

• Platform has demonstrated removal of multiple enveloped viruses (e.g., Ebola, H5N1, SARS-CoV-2) and is positioned as a potential early treatment for pandemic threats.

• Preclinical research supports use in Long COVID, platelet-derived microparticle removal, and organ transplantation, with evidence of EV and miRNA depletion.

• Hemopurifier could be integrated into machine perfusion platforms to improve renal transplant outcomes.